SLC5A2 and urinary tract infection: A meta‐analysis of 72 smaller RCTs found no difference in urinary tract infection rates between SGLT2 inhibitors and control groups, but indicated an increased risk of genital infections (RR, 3.37; 95% CI, 2.89 to 3.93).62